Related Experiment Video

Updated: Jun 3, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Troglitazone induces apoptosis in gastric cancer cells through the NAG-1 pathway

Chunhui Wang1, Jing Wang, Ping Bai

  • 1Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 61004, PR China. wangch@scu.edu.cn

Molecular Medicine Reports
|April 5, 2011
PubMed

Insights

Troglitazone inhibits gastric cancer cell proliferation and induces apoptosis. This effect is linked to increased expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) and Egr-1 protein levels.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Non-steroidal anti-inflammatory drug-activated gene (NAG-1) is a TGF-β superfamily member involved in cell proliferation and apoptosis.
  • Gastric cancer remains a significant health concern, necessitating research into novel therapeutic agents.

Purpose of the Study:

  • To investigate the effect of troglitazone on gastric cancer cell line BGC-823.
  • To elucidate the role of NAG-1 and Egr-1 in troglitazone-induced anti-cancer effects.

Main Methods:

  • Cell culture of BGC-823 gastric cancer cells.
  • MTT and TUNEL assays to assess cell proliferation and apoptosis.
  • Immunocytochemistry to evaluate NAG-1 and Egr-1 protein expression.

Main Results:

  • Troglitazone inhibited BGC-823 cell proliferation and induced apoptosis in a dose- and time-dependent manner.
  • Troglitazone treatment led to a concentration-dependent increase in NAG-1 expression.
  • Egr-1 protein levels were also elevated by troglitazone in a concentration-dependent fashion.

Conclusions:

  • Troglitazone demonstrates significant anti-proliferative and pro-apoptotic effects on BGC-823 gastric cancer cells.
  • The observed effects of troglitazone may be mediated, in part, through the Egr-1 pathway, involving NAG-1 expression.

More Related Videos

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker07:47

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker

Published on: September 15, 2023

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...